IP Litigation senior associate Jenny Zhang examine upcoming U.S. pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma companies looking to access the U.S. market in European Pharmaceutical Review.
Related Content
- AlertJune 10, 2024
JAMS Release Mass Arbitration Procedures Following AAA’s Lead
- AlertMay 31, 2024
Lawsuit Filed Challenging FDA Final Rule Regulating Laboratory Developed Tests
- Attorney ArticlesApril 24, 2024
Delaware Supreme Court Holds That Boards Must Satisfy the MFW Framework in Controller Transactions to Obtain Business Judgment Deference (Westlaw Today)
- AlertApril 15, 2024
Delaware Supreme Court Holds That Boards Must Satisfy the MFW Framework in Controller Transactions to Obtain Business Judgment Deference
- AlertJanuary 24, 2024
Updated AAA Rules and Fees Could Change the Mass Arbitration Landscape
- InsightJanuary 16, 2024
What’s Next for AI? Six Areas to Watch in 2024
- AlertAugust 21, 2023
Sixth Circuit Does Not Permit Third-Party Releases in Equity Receiverships
- Securities SnapshotJune 16, 2023
Second Circuit Upholds Dismissal of AstraZeneca Investor Suit
- Awards and RankingsJune 13, 2024
The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 187 Lawyers
- Press ReleaseJune 13, 2024
Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement
- Press ReleaseMay 29, 2024
Akili Interactive to Be Acquired by Virtual Therapeutics
- Press ReleaseMay 29, 2024
Marathon Oil Corporation to be Acquired by ConocoPhillips in an All-Stock Transaction Valued at $22.5 Billion
- Press ReleaseMay 24, 2024
Aktis Oncology and Eli Lilly Collaborate on Discovery and Development of Novel Anticancer Radiopharmaceuticals; Aktis To Receive $60 Million Upfront and up to an Additional $1.1 Billion in Potential Milestones
- Press ReleaseMay 13, 2024
DeMario Carswell Once Again Appointed to The ESOP Association’s Advisory Committee on Fiduciary Issues
- Speaking EngagementsMay 9, 2024
ACI's 19th FCPA & Anti-Corruption for the Life Sciences Industry
- Press ReleaseMay 9, 2024
Royalty Pharma To Acquire Royalty Interest In ImmuNext’s Frexalimab